Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study

@article{Burnier2009LessFD,
  title={Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study},
  author={M. Burnier and J. Douchamps and A. Tanghe and J. Demey and L. Perrault and Claire Foster and S. Robbins},
  journal={Journal of Medical Economics},
  year={2009},
  volume={12},
  pages={77 - 86}
}
Abstract Objective: To calculate the variable costs involved with the process of delivering erythropoiesis stimulating agents (ESA) in European dialysis practices. Methods: A conceptual model was developed to classify the processes and sub-processes followed in the pharmacy (ordering from supplier, receiving/storing/delivering ESA to the dialysis unit), dialysis unit (dose determination, ordering, receipt, registration, storage, administration, registration) and waste disposal unit. Time and… Expand
Cost-effectiveness of continuous erythropoietin receptor activator in anemia
  • H. Schmid
  • Medicine
  • ClinicoEconomics and outcomes research : CEOR
  • 2014
An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study
  • J. Galle, K. Claes, +8 authors M. Farouk
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012

References

SHOWING 1-8 OF 8 REFERENCES
Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States.
Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
  • A. Nissenson, S. Swan, +6 authors B. Maroni
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2002
Assessment of the impact of weekly versus monthly erythropoiesis stimulating protein therapy on patients with CKD and their families.
A feasibility cost-analysis study of recombinant human erythropoietin and darbepoetin alfa in ambulatory haemodialysis patients during current clinical practice
  • Eur J Hospital Pharm Sci 2006;12(3):47–51
  • 2006